At the news
? BULLISHIMPACT 7/10 6-K filed Jun 15, 2026 at 06:52 ET
AstraZeneca announced FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer. The approval is based on the CAPItello-281 Phase III trial showing a 19% reduction in risk of radiographic progression or death and a 7.5-month improvement in median rPFS versus standard of care. This expands Truqap into a second tumor type with a large addressable US patient population of approximately 35,000 annually, one in four of whom have PTEN-deficient tumors.
- FDA approved Truqap combination as first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
- CAPItello-281 trial showed 19% risk reduction in radiographic progression or death (HR 0.81; p=0.034)
- Median rPFS improved by 7.5 months (33.2 vs 25.7 months) versus abiraterone + ADT alone
- Approximately 35,000 US patients diagnosed annually with mAPMN/S prostate cancer; ~25% have PTEN-deficient tumors
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access